Priority Date: 13.02.13 (US 201361764308P)

IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

  • Application ID: EP14707841
  • Status: PATENT GRANTED

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Novartis Pharma AG is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 230 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 13.02.2013 - Priority Date (US 201361764308P)
  • 21.08.2014 - Publication A1 (WO2014125413)
  • 23.12.2015 - Publication A1 (EP2956455)
  • 17.05.2017 - Publication B1 (EP2956455)